ARTICLE | Clinical News
Zanolimumab: Phase III resumed
September 13, 2010 7:00 AM UTC
TenX resumed the second portion of an open-label, international Phase III trial to evaluate 14 mg/kg IV zanolimumab given weekly for 12 weeks in 70 patients. After suspending enrollment in 2008 while ...